Clostridium difficile infection future or investigational therapies
|
Clostridium difficile Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Clostridium difficile infection future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Clostridium difficile infection future or investigational therapies |
|
FDA on Clostridium difficile infection future or investigational therapies |
|
CDC on Clostridium difficile infection future or investigational therapies |
|
Clostridium difficile infection future or investigational therapies in the news |
|
Blogs on Clostridium difficile infection future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Genetics
On December 14, 2005, researchers at McGill University in Montreal, Quebec, led by Dr. Ken Dewar and Dr. Andre Dascal and in collaboration with province-organized NPO Genome Quebec's research facility, announced they had cracked the genetic code of the highly virulent Quebec strain of C. difficile. This was accomplished by using ultra high-throughput sequencing technology. The tests involved doing 400,000 DNA parallel sequencing reactions which took the bacterium's genome apart and reassembled it so it could be studied.[1][2]
It is expected this will allow quicker detection of the disease and better treatment.
References
- ↑ Invalid
<ref>tag; no text was provided for refs namedLoo_2005 - ↑ Scientists map C. difficile strain - Institute of Public Affairs, Montreal